{
  "docId": "019de072-1a15-7369-8097-68fb5b1d5017",
  "docSlug": "de0c004f3134112f269aa7aa17f1a1f3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 39,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "roadmap",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style chart to visualize drug development phases.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-1a15-7369-8097-68fb5b1d5017/30",
  "deckHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017",
  "deckJsonHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017.json",
  "deckAnchorHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.46,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Pipeline development chart showing various drug programs across Phase 1, 2, and 3.",
      "attrs": null,
      "subkind": "gantt-chart",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acd281d1-8db8-485c-a766-4b16aebbac88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.46,
        "x": 0.51,
        "y": 0.38
      },
      "kind": "list",
      "text": "US FDA accepted Ultomiris in generalised myasthenia gravis for priority review, PDUFA date in Q2 2022. Exclusive global license for NI006, novel depleter in development for ATTR amyloidosis. Investing in complement capabilities.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a38aed9-2ffe-4603-b6af-6a0d6117c5e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.31,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "FDA = Food and Drug Administration; PDUFA = Prescription Drug User Fee Act.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "697272e0-1663-47bc-a45b-0c07057ae905",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.77,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Late-stage weighted pipeline, multiple long-term growth opportunities",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e7b00ba-09bd-40dd-98f8-2f55d1ff1385",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.39,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Investing in Rare Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a30e230-6c02-494b-b1ea-a1b77c56f041",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Gantt chart",
      "slug": "gantt-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "8da9f470-30f7-480a-9341-82b1c26e86d3",
      "evidence": "chart/gantt-chart: Pipeline development chart showing various drug programs across Phase 1, 2, and 3.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "78fda452-fc5f-4ade-8475-bdea65409725",
      "evidence": "Visual representation of project timelines across phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 31,
      "from": 26,
      "beatId": "aad1cb9b-557b-4e95-ba5a-dc0050f283ae",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The closing remarks and Q&A session prompt action from the audience.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 26,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f69dbb94-83a9-490b-bc96-5831ed386c14",
      "evidence": "The presentation implies that not investing in the pipeline would mean missing out on growth opportunities.",
      "position": 1,
      "objective": "What are the consequences of not investing in AstraZeneca's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}